11:51 AM
 | 
Feb 14, 2018
 |  BC Extra  |  Clinical News

Galmed falls on Phase IIa HIV-associated NAFLD miss

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was down $4.01 (42%) to $5.45 on Wednesday after reporting that Aramchol arachidyl amino cholanoic acid missed the primary endpoint in the Phase IIa ARRIVE trial...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >